Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Resverlogix Corp
Bullboard Posts
User Avatar Image
(0)
•••
Comment by bull8888on Mar 01, 2007 2:24am
315 Views
Post# 12332257

RE: RVX $60 in 3 weeks-Billy

RE: RVX $60 in 3 weeks-Billy01001001 00100000 00100000 01101111 01101110 01101100 01111001 00100000 01101000 01100001 01110110 01100101 00100000 01100101 01111001 01100101 01110011 00100000 01101111 01101110 00100000 01110100 01101000 01100101 00100000 01100011 01100001 01110010 01110010 01101111 01110100 00101110 00100000 01001101 01100001 01110010 01100011 01101000 00100000 01110011 01101000 01101111 01110101 01101100 01100100 00100000 01101101 01100001 01101011 01100101 00100000 01111001 01101111 01110101 00100000 01101000 01100001 01110000 01110000 01111001 00100000 01000010 01000111 00101110
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities